浮针疗法联合康复治疗膝骨关节炎的临床研究

注册号:

Registration number:

ITMCTR2024000583

最近更新日期:

Date of Last Refreshed on:

2024-10-21

注册时间:

Date of Registration:

2024-10-21

注册号状态:

Registration Status:

补注册

Retrospective registration

注册题目:

浮针疗法联合康复治疗膝骨关节炎的临床研究

Public title:

Clinical Research of Treating KOA with Fu's Subcutaneous Needling and Rehabilitation Therapy

注册题目简写:

English Acronym:

研究课题的正式科学名称:

浮针疗法联合康复治疗膝骨关节炎的临床研究

Scientific title:

Clinical Research of Treating KOA with Fu's Subcutaneous Needling and Rehabilitation Therapy

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

卢得健

研究负责人:

卢得健

Applicant:

Dejian Lu

Study leader:

Dejian Lu

申请注册联系人电话:

Applicant telephone:

+85363507408

研究负责人电话:

Study leader's telephone:

+85363507408

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

83426746@qq.com

研究负责人电子邮件:

Study leader's E-mail:

83426746@qq.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

澳门镜湖马路33号镜湖医院中医科

研究负责人通讯地址:

澳门镜湖马路33号镜湖医院中医科

Applicant address:

Traditional Chinese Medicine Department of Kiang Wu Hospital ; No.33 Kiang Wu Road; Macau

Study leader's address:

Traditional Chinese Medicine Department of Kiang Wu Hospital ; No.33 Kiang Wu Road; Macau

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

澳门镜湖医院

Applicant's institution:

Kiang Wu Hospital

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2022-006

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

镜湖医院科研伦理委员会

Name of the ethic committee:

Research Ethics Committee of Kiang Wu Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2022/4/8 0:00:00

伦理委员会联系人:

彭洪泉

Contact Name of the ethic committee:

Hongquan Peng

伦理委员会联系地址:

澳门镜湖马路33号

Contact Address of the ethic committee:

Kiang Wu Hospital; No.33; Kiang Wu Road ; Macau

伦理委员会联系人电话:

Contact phone of the ethic committee:

+85366637902

伦理委员会联系人邮箱:

Contact email of the ethic committee:

hpeng93170@gmail.com

研究实施负责(组长)单位:

澳门镜湖医院

Primary sponsor:

Kiang Wu Hospital of Macau

研究实施负责(组长)单位地址:

澳门镜湖马路33号

Primary sponsor's address:

Kiang Wu Hospital; No.33; Kiang Wu Road ; Macau

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

澳门

市(区县):

Country:

China

Province:

Macau

City:

单位(医院):

澳门镜湖医院

具体地址:

澳门镜湖马路33号

Institution
hospital:

Kiang Wu Hospital

Address:

Kiang Wu Hospital; No.33; Kiang Wu Road ; Macau

经费或物资来源:

澳门科技基金和镜湖医院

Source(s) of funding:

FDCT and Kiang Wu Hospital

研究疾病:

膝骨关节炎

研究疾病代码:

Target disease:

Knee Osteoarthritis

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

1、通过临床随机对照实验观察浮针疗法治疗KOA的有效性;2、在常规VAS,WOMAC评分基础上增加膝关节屈伸肌力测定;膝关节主动活动度测定;力求评价指标更加客观化。3、通过跟指南推荐的康复治疗方法对照,验证浮针治疗膝骨关节炎的临床疗效,为浮针治疗膝骨关节炎提供客观科学的临床证据

Objectives of Study:

1. Observe the effectiveness of Fus subcutaneous needling(FSN) therapy in the treatment of KOA through randomised controlled trials; 2. Add the measurement of knee flexion and extension muscle strength and the measurement of knee joint active mobility on the basis of the conventional VAS and WOMAC scores and strive to make the evaluation indexes more objective; 3. Validate the clinical efficacy of FSN therapy for the treatment of osteoarthritis of the knee by comparing it with the rehabilitation treatment recommended by the guideline and provide objective and scientific clinical evidence for the treatment of osteoarthritis of the knee with FSN objective and scientific clinical evidence.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

(1)符合原发性单侧膝骨关节炎诊断标准; (2)膝骨关节炎分期评估为早中期; (3)年龄在50-80岁之间; (4)近1月未服用其他药物治疗及其它方式治疗者; (5)BMI<28; (6)VAS评分>3分; (7)患者患侧膝关节有自发性疼痛,触诊目标肌肉有硬结及条索感; (8)自愿并有能力签署知情同意书。

Inclusion criteria

(1) Fulfillment of diagnostic criteria for primary unilateral knee osteoarthritis; (2) Knee osteoarthritis staging assessed as early to mid-stage; (3) Aged between 50 and 80 years; (4) Those who have not taken other medication and other modalities of treatment in the last 1 month; (5) BMI <28; (6) VAS score >3; (7) Patients with spontaneous pain in the affected knee joint and hard knots and striations in the target muscles on palpation; (8) Voluntary and capable of signing an informed consent form.

排除标准:

(1)非原发性膝骨关节炎,如痛风性关节炎、血友病性关节炎等;因严重暴力(如车祸、高处坠落)导致膝关节结构破坏者; (2)近1月有使用过膝骨关节炎相关药物治疗及中医内、外治法,影响研究结果判断者; (3)近6月做过膝关节手术者; (4)同时有其他疾病伴有下肢疼痛者,如腰椎间盘突出、腰椎管狭窄症;合并有下肢血管病变者; (5)无法控制和/或诊断的内科情况,可能干扰或者影响研究治疗,如严重的肝、肾、心、脑疾病;未控制或未治疗的高血压(收缩压>160 mmHg 和/或舒张压>100 mmHg)、未控制或未治疗的糖尿病、营养不良、甲状腺功能亢进患者;或无法控制的精神疾病者; (6)拒绝或者不能接受浮针治疗或者短波等康复治疗者; (7)白血病、血小板减少等有出血倾向者; (8)严重的全身性或下肢局部皮肤疾病者。

Exclusion criteria:

(1) Non-primary knee osteoarthritis such as gouty arthritis hemophilic arthritis etc.; those who have structural damage to the knee joint due to severe violence (e.g. automobile accidents or falling from height); (2) Those who have used knee osteoarthritis related medication and Chinese medicine internal and external treatments in the last 1 month which affects the judgment of the study results; (3) Those who have had knee surgery in the last 6 months; (4) Those who also have other diseases with lower limb pain such as lumbar disc herniation lumbar spinal stenosis; combined with lower limb vascular lesions; (5) Uncontrolled and/or undiagnosed medical conditions that may interfere with or affect the study treatment such as severe liver kidney heart or brain disease; uncontrolled or untreated hypertension (systolic blood pressure >160 mmHg and/or diastolic blood pressure >100 mmHg) uncontrolled or untreated diabetes mellitus malnutrition or hyperthyroidism; or uncontrolled psychiatric disorders; (6) Those who refuse or are unable to receive rehabilitation therapy such as fsn therapy or short wave; (7) People with leukemia thrombocytopenia and other bleeding tendency; (8) Serious systemic or localized skin diseases of the lower limbs.

研究实施时间:

Study execute time:

From 2022-06-01

To      2024-06-30

征募观察对象时间:

Recruiting time:

From 2022-07-01

To      2024-04-30

干预措施:

Interventions:

组别:

短波组

样本量:

40

Group:

Short Wave Group

Sample size:

干预措施:

短波治疗

干预措施代码:

Intervention:

Short Wave

Intervention code:

组别:

浮针组

样本量:

40

Group:

FSN Group

Sample size:

干预措施:

浮针疗法

干预措施代码:

Intervention:

Fu's Subcutaneous Needling

Intervention code:

样本总量 Total sample size : 80

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

澳门

市(区县):

Country:

China

Province:

Macau

City:

单位(医院):

镜湖医院

单位级别:

私立医院

Institution/hospital:

Kiang Wu Hospital

Level of the institution:

Private Hospital

测量指标:

Outcomes:

指标中文名:

膝关节屈伸肌力

指标类型:

次要指标

Outcome:

knee flexion and extension muscle strength

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

膝关节活动度

指标类型:

次要指标

Outcome:

knee joint active mobility

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

疼痛视觉模拟标尺法

指标类型:

主要指标

Outcome:

Visual analogue Scales

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

WOMAC骨关节炎指数评分

指标类型:

次要指标

Outcome:

the western Ontario and McMaster universities osteoarthritis index

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

null

Tissue:

人体标本去向

其它

说明

Fate of sample 

Others

Note:

征募研究对象情况:

结束

Completed

年龄范围:

最小 50
Min age years
最大 80
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

采用随机对照方法,采用EXCEL中RAND()函数产生随机数得出随机数字表,将80例患者按就诊先后顺序进入随机数字表中对应的组别

Randomization Procedure (please state who generates the random number sequence and by what method):

The RAND () function in EXCEL was used to generate random numbers to derive a random number table and 80 patients were entered into the corresponding groups in the random number table according to the order of consultation.

盲法:

无盲法

Blinding:

No blinding

是否共享原始数据:

IPD sharing:

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

通过联络负责人获取

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

By Contact with the study leader

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

指定专人负责数据采集和管理

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Designate a person responsible for data collection and management

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统